University of Groningen

Vitamin B in Health Supplements and Neuropathy

van Hunsel, Florence; van de Koppel, Sonja; van Puijenbroek, Eugène; Kant, Agnes

Published in:
Drug Safety

DOI:
[10.1007/s40264-018-0664-0](https://doi.org/10.1007/s40264-018-0664-0)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van Hunsel, F., van de Koppel, S., van Puijenbroek, E., & Kant, A. (2018). Vitamin B in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases. *Drug Safety*, 41(9), 859-869. <https://doi.org/10.1007/s40264-018-0664-0>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Vitamin B₆ in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases

Florence van Hunsel¹ · Sonja van de Koppel¹ · Eugène van Puijenbroek^{1,2} · Agnes Kant¹

© Springer International Publishing AG, part of Springer Nature 2018

Abstract

Introduction In the literature, vitamin B₆ has been linked to the development of polyneuropathy. Most often, these complaints were seen when taking high doses of vitamin B₆ for a long time. Evidence as to whether a lower dosage range of vitamin B₆ (< 50 mg/day) can also induce neuropathy is scarce.

Objective We aim to comprehensively describe the cases of neuropathy associated with vitamin B₆ received by the Netherlands Pharmacovigilance Centre Lareb and to assess the case series concerning the use of vitamin B₆ and neuropathic complaints.

Methods We describe the number and nature of the reported cases, including suspect product, dosage, duration of use, and vitamin B₆ serum levels. In addition, we describe the causality for the individual cases (Naranjo Probability Scale) and for the entire case series (Bradford Hill criteria).

Results In total, 90 reports on products containing vitamin B₆ included at least one adverse drug reaction in the standardized Medical Dictionary for Regulatory Activities (MedDRA[®]) query (SMQ; broad) ‘peripheral neuropathy’. The amount of vitamin B₆ in the products varied between 1.4 and 100 mg per tablet. The serum vitamin B₆ level was known in 36 cases (88–4338 nmol/l), and the mean serum vitamin B₆ level was 907 nmol/l. However, no statistical

correlation between dosage and vitamin B₆ blood levels was found.

Discussion and Conclusion Causality assessment of the case series of 90 reports to Lareb shows it is plausible for the vitamin B₆ supplements to have caused complaints such as neuropathies. This is especially the case with higher dosages and prolonged use, but dosages < 50 mg/day also cannot be excluded.

Key Points

Many vitamin supplements on the market contain a vitamin B₆ dosage higher than the maximum acceptable intake of 25 mg for adults. The literature describes neuropathic complaints with long-term use (months to years), most often for dosages from > 50 mg/daily to multiple grams daily.

A case series of 90 Dutch spontaneous reports indicates that prolonged use (mean latency 2.2 years) of vitamin B₆, most often in dosages higher than the maximum acceptable intake of 25 mg for adults, is associated with neuropathic complaints.

✉ Florence van Hunsel
f.vanhunsel@lareb.nl

¹ Netherlands Pharmacovigilance Centre Lareb, 5237 MH 's-Hertogenbosch, The Netherlands

² Department of Pharmacy: Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands

1 Introduction

Vitamin B₆ is a water-soluble vitamin that functions as a coenzyme in many reactions involving amino acids, carbohydrates and lipid metabolism. The major vitamers of vitamin B are pyridoxine, pyridoxal, pyridoxamine and

their phosphorylated derivatives pyridoxine 5'-phosphate (PNP), pyridoxal-5'-phosphate (PLP) and pyridoxamine-5'-phosphate (PMP) [1].

A Dutch National Food Consumption survey in the Netherlands showed that the intake of vitamin B₆ was sufficient in the whole population in the period 2007–2010 [2]. However, on an individual level, deficiencies in vitamin B₆ may arise from insufficient intake or malabsorption or because of drugs such as isoniazid that inhibit enzymes involved in the metabolism of PLP, the active vitamer of vitamin B₆ [3, 4]. Certain groups, such as the elderly or patients with alcoholism, might have low vitamin B₆ blood levels [5]. Many hospitals in the Netherlands use 51–183 nmol/l as the reference values for vitamin B₆ blood levels [6].

Although vitamin deficiency is rare in the Netherlands [2], 27–56% of the study population in the previously mentioned Dutch Food Consumption survey reported the use of dietary supplements such as vitamins. About half of women aged ≥ 19 years used dietary supplements [2].

The recommended daily allowance for vitamin B₆ for men and women aged 19–50 years in the Netherlands is 1.5 mg if daily protein intake is 100 g [7]. The maximum acceptable intake is 25 mg for adults [7, 8].

In the literature, vitamin B₆ has been linked to the development of polyneuropathy [9–12]. Most often, these complaints were seen when high doses of vitamin B₆ were used for a longer period of time [1, 11, 12]. A review of the literature stated that vitamin B₆ used for > 6 months and at doses > 50 mg/day is probably harmful [13]. Evidence as to whether a lower dosage range of vitamin B₆ (< 50 mg/day) can also induce neuropathy is scarce.

The Netherlands Pharmacovigilance Centre Lareb has received 90 reports on neuropathy associated with vitamin B₆, for a range of products with a variety of vitamin B₆ levels. Most vitamin products on the Dutch market are not registered as drugs through the Dutch Medicines Evaluation Board (MEB) but are governed by the Dutch Commodities Act. Lareb shares the reported adverse reactions related to these products with the Netherlands Food and Consumer Product Safety Authority (NVWA) [14]. Earlier pharmacovigilance activities led to multiple signals on the relation between vitamin B₆ in food supplements and neuropathic complaints, which were communicated to the NVWA [15, 16]. The aim of this article is to comprehensively describe the cases received and assess the case series concerning the use of vitamin B₆ and neuropathic complaints.

2 Methods

2.1 Selection of Cases

We studied all adverse drug reactions (ADRs) related to neuropathy and health supplements that contain vitamin B₆ reported to Lareb from 1991 (establishment of the center) until July 2017. Reports in the Dutch spontaneous database are coded using Medical Dictionary for Regulatory Activities (MedDRA[®]) codes [17] and individually assessed for causality by trained assessors. All (multi)vitamin products containing vitamin B₆ were selected and included for review if they contained an ADR coded with a MedDRA preferred term (PT) within the MedDRA version 20.1 standardised MedDRA query (SMQ) 'peripheral neuropathy' (broad) [18]. This SMQ can be used to select ADRs related to impairment of the peripheral motor, sensory and autonomic nervous system.

2.2 Description of the Cases

We describe the number and nature of the reported cases, including suspect product with dosage and duration of use, latency period, comedication, age and sex of the patient, seriousness of the ADR according to Council for International Organizations of Medical Sciences (CIOMS) criteria [19], de- and rechallenge information and vitamin B₆ serum levels. The correlation between milligrams of vitamin B₆ in the products and serum vitamin B₆ levels was assessed using a Pearson correlation coefficient.

In addition, we describe the causality for both the individual cases and the entire case series. The causality of cases received by Lareb is assessed on a case-by-case manner, which also includes documenting the score on the Naranjo Probability Scale [20], a quantitative tool used to estimate the likelihood that an ADR is actually due to the drug; these scores are given for the reports.

2.3 Causality of the Case Series

We assessed the case series using the Bradford Hill criteria [21]. These criteria included the strength of the association, consistency of the cases, specificity of the association, temporality, dose–response relationship, plausibility of the association, coherence, experiment and analogy.

In terms of strength of the association, the larger the association between exposure and risk, the greater the likelihood of the association being causal [22]. It is not possible to calculate an incidence or risk when using a spontaneous reporting database. An approximation for the strength of the association is calculating the disproportionality of the reported association in the database, which

can be determined in multiple ways. Unfortunately, the manner of coding means it is not possible to distinguish separate health supplements and it is therefore not possible to calculate disproportionality in the Lareb database. Therefore, we used the global database Vigibase[®] instead, in which health supplements are coded separately. We obtained numbers of reports and information component (IC) values for the selected PTs through Vigilyze[®], a search and analysis tool (available to countries that are members of the World Health Organization [WHO] Programme for International Drug Monitoring). IC₀₂₅ is the lower end of a 95% credibility interval for the information component. A positive IC₀₂₅ value is the traditional threshold used in statistical signal detection at Uppsala Monitoring Centre (UMC); we therefore used these values as an indicator for disproportionality [23, 24].

The consistency of the association in the Lareb database with previous findings in other sources was assessed by reviewing the literature on this topic and comparing the spontaneous cases from the Dutch pharmacovigilance database with those from the literature. A structured literature search was conducted using a text search in PubMed, with the keywords vitamin B₆, pyridoxine, and neuropathy. There was no restriction on the time of publication nor initially on language, and only studies in humans were selected. This yielded an initial list of 189 articles. We checked whether known key publications were identified with this search. Publications were selected based on the title of the publication and keywords ($n = 40$ in total). One article was thereafter excluded because it was only available in Japanese. Abstracts of the remaining identified studies and case reports were then assessed for relevance to the scope of the review. We also checked the references of key publications to obtain articles not found with our previous search. The full paper was obtained for each study being considered for inclusion in the review.

3 Results

3.1 Description of the Cases

A total of 139 reports on food supplements/multivitamin products containing vitamin B₆ were selected. Of these, 90 reports contained at least one ADR in the SMQ ‘peripheral neuropathy’. In the reports, 18 patients were male (20%) and 72 were female (80%). Mean age was $53.2 \pm$ standard deviation (SD) 15.7 years; range 3–85. In total, 14 cases were serious according to CIOMS criteria, mainly because of the disabling character of the ADR (see Fig. 1).

The latency period was known in 57 cases. The mean latency period was 807 days (2.2 years) with an SD of 1461 days (4.0 years) and a range between ‘minutes after

start’ to 23 years. Eight cases had a latency period of ≤ 2 months.

The amount of vitamin B₆ in the products ranged from 1.4 to 100 mg per tablet, but intake could be higher than 100 mg because the patient might have taken multiple tablets. For instance, one patient used one tablet of 75 mg and one of 50 mg vitamin B₆. One report considered a liquid dosage form with 0.4 mg vitamin B₆/100 ml. In five products, the amount of vitamin B₆ was not given in milligrams but as a percentage of the recommended daily dose; this varied between 200 and 4000%. In 38 cases, the dosage of vitamin B₆ in the products was equal to or higher than the maximum acceptable daily intake of 25 mg for adults [7], and 22 of these cases had a dosage ≥ 50 mg. The dosage was unknown in 27 cases.

The serum level of vitamin B₆ was known in 36 cases. These varied from 88 to 4338 nmol/l. In all but two cases (88 and 145 nmol/l), the reported serum levels were higher than the reference values of 51–183 nmol/l [6]. Mean serum vitamin B₆ level was 907 nmol/l, and the median was 945 nmol/l. Both the dosage and the serum level of vitamin B₆ was known in 29 cases. However, no statistically significant correlation between the serum vitamin B₆ level and the milligrams of vitamin B₆ in the product could be found (Pearson correlation $r = -0.876$, $p = 0.65$).

The highest serum value was reported by a general practitioner from a 63-year-old woman who had used a product with pyridoxine 50 mg daily for 2 years before she developed neuropathy. In two patients, reported serum levels decreased after vitamin B₆ was withdrawn; for example, a female aged 24 years without concomitant medication reported neuropathy following the use of vitamin B₆ 75 mg daily. After 2.5 months of use, her vitamin B₆ serum level had increased to > 500 nmol/l. After vitamin B₆ was withdrawn, her serum level decreased to 261 nmol/l after a month and she was recovering from her complaints. In total, 30 positive dechallenges were reported; one rechallenge was reported.

The outcome for the causality score of the individual cases using the Naranjo Probability Scale [20] was ‘probable’ in eight (9.9%) and ‘possible’ in 82 cases (91.1%). No cases had a Naranjo score of ‘unlikely’.

3.2 Causality of the Cases Series

Using the Bradford Hill criteria [21], we assessed the strength of the association, consistency of the cases, specificity of the association, temporality, dose–response relationship, plausibility of the association, coherence, experiment and analogy (Table 1).

Criteria 1: Strength of Association On 4 July 2017, Vigilyze[®] included 282 cases for the substance pyridoxine and the SMQ ‘peripheral neuropathy’. The SMQ

Fig. 1 Description of the selected cases. *ADR* adverse drug reaction, *SMQ* standardized MedDRA query

Table 1 Causality assessment of the case series of vitamin B₆-induced neuropathy using the Bradford Hill criteria

Criteria	Discussion
Strength of association	In the global pharmacovigilance database, Vigilyze [®] , 282 cases for the substance pyridoxine and SMQ 'peripheral neuropathy' with positive IC ₀₂₅ value for hypoesthesia (<i>n</i> = 24; IC ₀₂₅ = 1.23), paraesthesia (<i>n</i> = 102; IC ₀₂₅ = 0.87), neuropathy peripheral (<i>n</i> = 39; IC ₀₂₅ = 0.81), polyneuropathy (<i>n</i> = 7; IC ₀₂₅ = 0.68) and muscular weakness (<i>n</i> = 44; IC ₀₂₅ = 0.60). This is supportive for an association
Consistency	This case series of Dutch ADR reports is consistent with previous reports from the literature (clinical studies, case series and case reports). The reactions had a similar pattern in clinical features and time to onset. This is supportive for an association. However, reported dosages were sometimes lower than generally described in the literature. No epidemiological studies were found
Specificity	In the 90 reports, a total of 188 ADRs were reported. Mostly these ADRs were nervous system disorders related to neuropathy. Few non-related ADRs were reported. This is supportive for an association. In 43 cases, no concomitant medication was reported. This does not exclude that concomitant use of drugs previously associated with neuropathy can be an alternative explanation. In nine cases, patients used a statin concomitantly, for which neuropathy is a known ADR
Temporality	All reactions manifested after the suspected drug was administered, and time to onset of reactions was usually after a prolonged period, the mean latency period was 807 days (2.2 years) ± SD 1461 days (4.0 years). This is supportive for an association
Biological gradient (dose–response relationship)	Serum vitamin B ₆ levels were known in 36 cases and higher than reference values in 34 cases. However, no statistical correlation between dose and vitamin B ₆ blood levels was found
Plausibility	A recent study (2017) indicated that the neuropathy observed after taking a relatively high dose of vitamin B ₆ supplements is due to pyridoxine. Vrolijk et al. [1] stated that "The inactive vitamer pyridoxine competitively inhibits the active PLP. Consequently, symptoms of vitamin B ₆ supplementation are similar to those of vitamin B ₆ deficiency." [1] This is supportive for an association
Coherence	The reasoning about cause and effect as present in the aforementioned criteria are in line with each other and supported by the existing knowledge. This supports the existence of a causal relationship
Experiment	30 positive dechallenge cases, one rechallenge, which was positive. This criterion is of limited value as there is almost no information about experiments with rechallenges
Analogy	This criterion is of limited value here as there is no analogous agent to vitamin B ₆

ADR adverse drug reaction, *IC₀₂₅* lower end of a 95% credibility interval for the information component, *SD* standard deviation, *SMQ* standardized MedDRA query

incorporated cases with 22 different MedDRA[®] PTs. Five PTs had a positive IC₀₂₅ value: hypoesthesia (*n* = 24; IC₀₂₅ = 1.23), paraesthesia (*n* = 102; IC₀₂₅ = 0.87),

neuropathy peripheral (*n* = 39; IC₀₂₅ = 0.81), polyneuropathy (*n* = 7; IC₀₂₅ = 0.68) and muscular weakness (*n* = 44; IC₀₂₅ = 0.60). As shown in Table 2, associations

with the largest number of reports and generally most specific for chronic neuropathy are disproportionally present, which is supportive of an association.

Criteria 2: Consistency of the Cases Most of the available literature on vitamin B₆ and neuropathy is based on case series, case reports, and (small) clinical studies. A limited number of clinical studies have also been conducted without finding neuropathy related to vitamin B₆ use [25–27]. However, a review of these studies by the Scientific Committee on Food of the European Commission stated that many of these were of insufficient duration, did not assess symptoms sufficiently rigorously to be of value, had a small group size or provided no data on possible pyridoxine neuropathy [28].

This case series of Dutch ADR reports has a pattern in clinical features and time to onset similar to those of published cases. Reported dosages in the literature vary from 24 mg [9] to extremely high dosages of multiple grams used daily [29–31]. In 37 of the reports to Lareb, the vitamin B₆ dosage in the products was equal to or higher

than the maximum acceptable intake of 25 mg for adults [8] but generally lower than the mega doses described in the literature (see Table 3). In 25 cases, the dosage per tablet was < 25 mg, but patients might have taken multiple dosage forms.

Criteria 3: Specificity Using a broad SMQ is not a very specific method to pinpoint an ADR. In addition, an ADR report can contain multiple ADRs. Many of the cases described neuropathy, peripheral neuropathy, or polyneuropathy without describing all the symptomatology, and other cases described neuropathic pain, paresthesia, burning sensations, numbness or tingling of extremities. For instance, “tingling of legs aggravating to muscle weakness of lower limb” and “numbness of extremities (arm and thumb) and neuropathic pain” or “numbness in leg and balance difficulty.” Other cases described symptoms in association with an elevation of their vitamin B₆ level: “B₆ increased and burning sensation in the foot and lower leg and numbness of the big toe” and “tingling of extremity (lower legs) and vitamin b₆ increased (three times above the normal level).”

Many patients specified that they were seen by a neurologist, but few diagnostic test results for neuropathy were reported. One patient 45-year-old woman reported neuropathy following 3.5 years of vitamin B₆ use. Electromyogram (EMG), magnetic resonance imaging (MRI), ultrasound, and lumbar puncture showed no abnormalities, but the vitamin B₆ content in her blood was high (> 500 nmol/l). The following symptoms were reported as attributed to the neuropathy: strange feeling in right thigh, sensory disturbance, muscle twitching, involuntary muscle movements in rest, burning pain in both knees and fibula cups, burning pain, mushy feeling buttocks and painful hips after sleep. The patient had recovered almost completely 2.5 years after cessation of the vitamin supplements.

Another woman (aged 74 years) reported small fiber peripheral neuropathy with symptoms: coldness of limbs and tingling of extremity (tingling feet, aching feet, very difficult to walk) following administration of vitamin B₆ with a latency of 4 months after start. EMG was not abnormal, abnormal warm and cold sensation thresholds were suggestive of small-fiber neuropathy according to her neurologist. Vitamin B₆ was withdrawn. The patient was treated with gabapentin, triamcinolone injection and physiotherapy. At the moment of reporting she had not recovered.

One patient experienced a burning sensation all over the body, which meant the case was selected with the SMQ used, but the short latency period and treatment indicates that an allergic reaction was more likely than an acute neuropathy. Concomitant medication was reported in 47 cases, and a relation with some of the concomitantly used drugs such as statins cannot be ruled out.

Table 2 Disproportionality on MedDRA® preferred term level of the cases within the standardized MedDRA query ‘peripheral neuropathy’ in the global individual case safety reports database Vigibase® (data extraction 4 July 2017)

Reaction (PT)	No. observed	IC ₀₂₅
Hypoesthesia	94	1.23
Paraesthesia	102	0.87
Neuropathy peripheral	39	0.81
Polyneuropathy	7	0.68
Muscular weakness	44	0.60
Peripheral sensory neuropathy	4	− 0.13
Acute polyneuropathy	2	− 0.35
Neuritis	3	− 1.23
Neuralgia	3	− 2.15
Polyneuropathy chronic	1	− 2.24
Burning sensation	6	− 2.40
Sensorimotor disorder	1	− 2.42
Gait disturbance	10	− 2.46
Axonal neuropathy	1	− 2.48
Peripheral sensorimotor neuropathy	1	− 2.53
Hypotonia	3	− 2.91
Areflexia	1	− 3.49
Dysesthesia	1	− 3.88
Sensory loss	1	− 3.97
Muscle atrophy	1	− 4.38
Sensory disturbance	1	− 5.17
Skin burning sensation	1	− 5.30

IC₀₂₅ lower end of a 95% credibility interval for the information component, PT MedDRA preferred term

Table 3 Literature on vitamin B₆-related neuropathy

Study (type of study)	Pt numbers and characteristics	Vitamin B ₆ dosage	Duration of use before reaction	Description of neuropathy
Schaumburg et al. [46] (1983) (case series)	Seven healthy adults aged 25–47 y	2–6 g/d	Mo	Ataxia and severe sensory-nervous-system dysfunction. Four were severely disabled; all improved after withdrawal. Nerve biopsies in two pts showed widespread axonal degradation
Dalton [47] (1985) (case series)	58 women with PMS	50–500 mg	–	Reduction of neuropathic complaints 2 mo after stopping vitamin B ₆
Foca [31] (1985) (case report)	One 81-y-old woman, indication treatment for carpal tunnel syndrome	Gradually increasing dose to 4.5 g/day	Mo	Nerve conduction studies revealed slowing of motor conduction velocities, prolonged F-wave latencies, prolonged sensory latencies in both lower extremities
Parry and Bredesen [48] (1985) (case series)	16	0.2–5 g/d	Varied	Pure sensory central–peripheral distal axonopathy. Improvement after discontinuation of pyridoxine noted for pts who were followed for longer
De Zeghler et al. [49] (1985) (case report)	One 1-y-old girl	At 9 wk, dose increased from 400 to 1000 mg daily	1 wk	After 1 wk on higher dosage of pyridoxine 1000 mg/d, pt had become areflexic; EEG was abnormal. Pyridoxine blood levels were too high. Recovered after dosage was lowered to 400 mg
Friedman et al. [50] (1986) (case report)	One woman with menstrual water retention syndrome	2 g/d	2 y	Sensory peripheral neuropathy, recovered after discontinuing vitamin B ₆
Dalton and Dalton [12] (1987) (case–control study)	172: women with PMS taking vitamin B ₆ , cases with neurological symptoms, controls without symptoms	<50 to < 500 mg	<6 mo to > 5 y	Raised serum B ₆ level in 103 women, 60% of whom had neurological symptoms, which disappeared when B ₆ was withdrawn and reappeared in four cases when B ₆ was restarted. Mean dose taken by cases and controls was comparable, cases had taken vitamin B ₆ for a significantly longer period
Waterston and Gilligan [51] (1987) (case report)	One 20-y-old woman	1000 mg/d for 12 mo	–	Sensory neuropathy, 4 mo after drug cessation marked recovery
Albin et al. [52] (1987) (case report)	Two pts, both treated for mushroom intoxication	Patient 1: 132 g IV over 3 d Patient 2: 183 g IV over 3 d		Both developed an acute, severe and permanent sensory deficit
Santoro et al. [53] (1991) (case report)	One 54-y-old man, treatment for PTB with isoniazid 400 mg/d	600 mg/d	Mo	No recovery 8 mo after withdrawal from isoniazid. However, improvement after discontinuation of pyridoxine. Recovery was slow and still incomplete after 4 y
Berger et al. [54] (1992) (case series)	Five healthy volunteers	Either 1 or 3 g/d	≤7 mo	In all pts, sensory symptoms and QST abnormalities occurred concurrently and were dose related
Morra et al. [30] (1993) (case report)	One 50-y-old woman	10 g/d	5 y	Severe sensory and mild motor neuropathy consisting of loss of touch, temperature, pin-prick, vibration and joint-position in all extremities in a stocking-glove distribution and slight ataxia

Table 3 continued

Study (type of study)	Pt numbers and characteristics	Vitamin B ₆ dosage	Duration of use before reaction	Description of neuropathy
de Kruijk and Notermans [9] (2005) (case report)	Two men, 60 and 65 y	24 and 40 mg/d, respectively	Y	One pt with bilateral numbness in hands and leg pain. Serum level 126 nmol/l (reference value: 35–110). Other pt with painful tingling in legs. Serum level > 500 nmol/l (reference value 35–110)
Wyatt et al. [55] (1999) (systemic review of published and unpublished PL-controlled RCTs)	526 women with PMS	50–600 mg	≤4 mo	One case neurological side effects
Scott et al. [10] (case series)	26	20 pts (76.9%) reported daily vitamin use; dosage unknown	Unknown	26 pts with sensory complaints had elevated serum B ₆ levels (mean 68.8 ng/ml). 21 pts (80.8%) reported only sensory complaints. Nine of 26 had abnormal EMG/NCS. Eight patients had an abnormal QST
Gdynia et al. [29] (2008) (case report)	One 75-y-old man	9.6 g/d	3 y	Pyridoxine blood level was 1850 µg/l (normal 40–120 µg/l). Muscle weakness and motor findings on electrophysiological testing suggested a pure sensory neuronopathy
Kulkantrakorn [11] (2014) (case series)	Three pts aged 80, 83 and 83 y	600 mg/d	3–10 y	Markedly elevated vitamin B ₆ blood levels. Electrodiagnostic tests showed symmetric axonal sensory polyneuropathy in two pts. 2 y after vitamin B ₆ discontinuation, pts had not recovered
Visser et al. [33] (2014) (case–control study)	381 pts with CIAP vs. 140 healthy controls	Vitamin B ₆ use and levels in pts vs. controls	–	Vitamin B ₆ levels in pts, daily dose, cumulative dose, duration of supplement use not significantly higher vs. controls. More pts (31%) than controls (22%) used vitamin B ₆ -containing supplements
Bacharach et al. [56] (2017) (case report)	One 41-y-old woman	B ₆ supplement (dosage unknown) and energy drink (B ₆ 2000% of DRD)	Mo	Pyridoxic acid blood level of 463 mg/l (normal 3–30 mg/l), 2 y of progressive burning pain, numbness, tingling, and weakness in a stocking-glove distribution. EMG/NCS demonstrated chronic sensory polyneuropathy

CIAP chronic idiopathic axonal polyneuropathy, *d* day(s), EEG electroencephalogram, EMG electromyogram, IV intravenous, *mo* month(s), NCS nerve Conduction Studies, PL placebo, PMS premenstrual syndrome, *pt(s)* patient(s), PTB pulmonary tuberculosis, QST quantitative sensory testing, RCT randomized controlled trial, *wk* week(s), *y* year(s)

Criteria 4: Temporality The most common form of neuropathy is axonal degeneration, which occurs over weeks to months after exposure to a suspect drug [32]. Furthermore, in the literature, reported latency periods for drug-induced neuropathy are generally months to years as shown in Table 3. Therefore, cases with a very short latency period ($n = 8$) are not supportive of a causal

relation. However, most cases ($n = 82$) had a supportive latency.

Criteria 5: Biological Gradient (Dose–Response Relationship) A dose–response relationship increases the likelihood of a causal relation [22]. However, no statistically significant correlation between the serum vitamin B₆ level and the milligrams of B₆ in the product could be found.

Since some cases reported (very) high serum B₆ levels for low dosages, we cannot exclude that patients took multiple dosages of the product per day or that the declaration of the milligrams on the package of the product was incorrect.

Criteria 6: Plausibility Vrolijk et al. [1] studied the neurotoxicity of the different forms of vitamin B₆ in in vitro models. Cells were exposed to pyridoxine, pyridoxamine, pyridoxal, PLP or PMP for 24 h, after which cell viability was measured. Vrolijk et al. [1] stated that “this study indicated that the neuropathy observed after taking a relatively high dose of vitamin B₆ supplements is due to pyridoxine. The inactive form pyridoxine competitively inhibits the active PLP. Consequently, symptoms of vitamin B₆ supplementation are similar to those of vitamin B₆ deficiency”. This plausible mechanism is supportive of an association.

Criteria 7: Coherence Histopathological changes present in cases of neuropathy can be explained by existing theories and are in line with the presence of dose dependency and time to onset of the reaction.

Criteria 8: Experiment Working with spontaneously reported ADRs, we do not have evidence based on randomized experiments. Instead, information, especially on positive rechallenges and, to a lesser extent, positive dechallenges might be viewed as supportive information for this criterion. In total, 30 positive dechallenges were reported. However, since (poly)neuropathy can be irreversible, information on dechallenges is of limited value. In 29 cases, there was no positive dechallenge, meaning the product was withdrawn but patients had not recovered at the time of reporting. In the other cases, information on dechallenge was unknown. Only one rechallenge was performed, which was positive. One patient had used a vitamin B₆ supplement in the past, which led to elevated vitamin B₆ blood levels that recovered after cessation of the product. The second time she used a vitamin B₆ product, her blood levels increased again and this time she experienced numbness and pain in her feet.

Criteria 9: Analogy This criterion is of limited value here, as there is no analogous agent to vitamin B₆.

4 Discussion

4.1 What is Already Known?

Polyneuropathy related to decreased levels of vitamin B₆ is well known. In contrast, the association between elevated levels of pyridoxine and neuropathy is less known [10]. Vrolijk et al. [1] stated that, “remarkably, sensory neuropathy is seen in vitamin B₆ toxicity as well as vitamin B deficiency.” The toxic effects of pyridoxine depend on both the dose and the duration of intake [13].

Several case series have described neuropathy as an effect of elevated vitamin B₆ levels, albeit with extremely high doses of vitamin B₆ in some cases. However, literature also exists on prolonged use of vitamin B₆ in patients who did not develop neuropathy [26]. Evidence is largely based on case reports, case series and clinical studies, as seen in Table 3, all with their own limitations. Larger epidemiological studies are lacking. One case–control study published in 2014 [33] investigated vitamin B use in patients with chronic idiopathic axonal polyneuropathy (CIAP) versus healthy controls. On the basis of this study, an association between CIAP and vitamin B₆ exposure or elevated vitamin B₆ levels appeared unlikely. However, most reports from the literature concern patients with a (severe) sensory ataxic neuropathy, which is quite different from the phenotype seen in CIAP, where sensory ataxia is not a prominent feature [33]. As with all adverse reactions, the dosage and timing at which patients are prone to develop adverse reactions is subject to a patient’s individual susceptibility.

4.2 What Does this Study Add?

This study adds a large case-series of 90 reports to the existing evidence on vitamin B₆-induced neuropathy and an extensive review of the literature on this topic.

Causality assessment in pharmacovigilance is challenging. But, as Edwards has recently said, “The fullest assessment of clinical cases still gives critical information useful to clinicians” [34]. For this article, we conducted a causality assessment of the case series of 90 spontaneously reported cases of vitamin B₆-induced neuropathy. All cases were individually assessed by trained assessors, and we included the score on the Naranjo algorithm [20] and an assessment according to the Bradford Hill criteria [21]. The Naranjo algorithm is still the most widely used causality methods, although its performance in capturing the causal relation for all types of spontaneous ADRs is debatable [35–37]. We found the Bradford Hill criteria [21] to be a valuable tool in this assessment, but we made some adjustments to the original criteria he proposed. Because an incidence or risk for this association was not available, an indicator value for disproportionate reporting was used to get an impression about the strength of this association among the reported cases in Vigibase®. Indeed, this IC value and related measures of disproportionality are used by the UMC and other pharmacovigilance centers merely for statistical signal detection [23, 24]. Like any other value of disproportionality, the IC informs the strength of the association in the dataset under study. Of course, this does not necessarily imply a causal relationship in the population of those using the drug, but it may be indicative for one [38]. It goes without saying that other supportive

information is needed for the assessment of causality. Russom et al. [39] used a similar approach in the assessment of a case series.

We could not fully assess all the Hill criteria for this case series. However, Bradford Hill [21] stated,

“None of these nine viewpoints can bring indisputable evidence for or against a cause and effect hypothesis What they can do, with greater or less strength, is to help answer the fundamental question—is there any other way of explaining the set of facts before us, is there any other answer equally, or more, likely than cause and effect?”

The information throughout the cases is generally consistent, and many cases included laboratory values. More than 75% of the reports were made by patients themselves, showing their value as reporters of useful drug safety information.

In 36 cases, the serum level of vitamin B₆ was known. These varied from 88 to 4338 nmol/l and was above reference values in 34 cases. Interestingly, Lareb has received reports of neuropathy even at relatively low dosages of vitamin B₆. In 38 cases, the dosage of vitamin B₆ in the products was equal to or higher than the maximum acceptable intake of 25 mg for adults [8], and 22 of these cases had a dosage $\geq$ 50 mg.

The study by Vrolijk et al. [1] indicated that the toxicity of vitamin B₆ is determined not only by the dose but also by the vitamin in which it is taken. They suggested that “perhaps it might be better to replace pyridoxine by pyridoxal-5'-phosphate or PLP as vitamin B₆ supplements, which are much less toxic. In this way, the vitamin B₆ paradox may potentially be prevented.”

4.3 Maximum Safe Daily Dose

When determining the maximum safe daily dose of vitamin B₆, the total intake per day is used, thus dietary intake and any intake via supplements. There is a large margin between the European Food Safety Authority (EFSA)-established safe upper limit of vitamin B₆ 25 mg per day and the intake of B₆ through the diet [8, 40]. In a Dutch National Food Consumption survey, the median vitamin B₆ intake from foods ranged from 1.4 to 2.2 mg/day for men and from 1.3 to 1.8 mg/day for women. Accounting for vitamin B intake from dietary supplements increased this by 5–17% at the median (1.5–2.4 mg/day for men and 1.4–2.1 mg/day for women for total vitamin B₆ intake) [2]. About 1% of Dutch women exceed the safe upper limit by using vitamin supplements [2]. Food supplements, including vitamins, are used by a large number of people. Because dietary supplements are sold over the counter without a prescription, consumers may incorrectly assume they carry no risk [41]. Although many manufacturers of

food supplements adhere to the recommended safe upper limit of pyridoxine 25 mg, Lareb's reports show that a fair amount of products on the Dutch market also exceed this upper limit. Lareb's reports were used in an advice to the Dutch Minister of Health that the maximum allowed dosage of vitamin B₆ in supplements should be set at 21 mg [42]. The Dutch Minister of Health agreed in December 2016 that this advised maximum allowed dosage of vitamin B₆ will be laid down in a law [43].

4.4 Limitations of the Study

Our main limitation is that we were not able to check whether the amount of vitamin B₆ declared on the product's packaging was the actual amount in the product or whether the patient took more than the advised dosage on the package and did not declare this in their ADR report. This could be the reason that no correlation was found between the milligrams of vitamin B₆ used and the reported vitamin B₆ serum levels. We also do not have information on the exact composition of the products, considering which vitamins are present.

However, it is also possible that, for some patients, the use of vitamin B₆ was not the (main) cause of the reported neuropathic complaints. The causes for developing peripheral neuropathy are myriad; Bernstein [44] stated that prior susceptibility might be a reason why some patients develop neuropathies relating to vitamin B₆ while others do not. Pre-disposing factors might consist of family histories and drug, alcohol and nutritional status [44]. Many reports of peripheral neuropathy were patient-reported and—although many contained information on vitamin B₆ blood levels—were not supported by a physician's assessment or electrodiagnostic data. During the case-by-case assessment of the reports, follow-up was requested in many cases, but these are mainly patient's reports, so we do not have detailed data on clinical examinations. Our center does not routinely ask for medical confirmation of reports received from patients [45]. In 36 of the 90 reports of peripheral neuropathy in patients receiving vitamin B₆, the B₆ serum level was known. It is possible that patients developed a peripheral neuropathy such as CIAP coincidentally. We have no information from the cases that any of the patients had vitamin deficiency, but we cannot be sure of this. In two cases, alcoholism was reported, and vitamin B deficiency is a known problem with this condition [44]. Similarly, we only know the dosage of B₆ in 37 cases, for the others, whether patients may or may not have been taking the recommended daily dose is unknown.

Unfortunately, it is not possible to relate the number of cases to the number of users in the Netherlands. No comprehensive data are available on sales of these products,

including web sales from a multitude of vendors. Based on our reports, we are unable to assess the magnitude of the actual risk of the adverse effects at the dose considered the maximal acceptable intake.

5 Conclusion

Causality assessment of a case series of 90 reports to Lareb indicates it is plausible that vitamin B₆ supplements may cause complaints such as neuropathies. This is especially so with higher dosages and prolonged use, as is also known from the literature, but causality cannot be excluded for dosages < 50 mg/day. Because high-dosage vitamin B₆ supplements are readily available for consumers, it is important consumers are made aware of the possible risks associated with the use of these products.

Compliance with ethical standards

Conflict of interest Florence van Hunsel, Sonja van de Koppel, Eugène van Puijenbroek and Agnes Kant have no conflicts of interest.

Funding No sources of funding were used to assist in the preparation of this study.

References

1. Vrolijk MF, Opperhuizen A, Jansen EHJM, Hageman GJ, Bast A, Haenen GRMM. The vitamin B₆ paradox: supplementation with high concentrations of pyridoxine leads to decreased vitamin B₆ function. *Toxicol In Vitro*. 2017;44:206–12.
2. van Rossum CTM, Fransen HP, Verkaik-Kloosterman J, Buurma-Rethans EJM, Ocke MC. Dutch National Food Consumption Survey 2007–2010: Diet of children and adults aged 7 to 69 years. RIVM Rapport 350050006, 1–144. 7-7-2012. RIVM. Ref Type: Report.
3. van der Watt JJ, Benatar MG, Harrison TB, Carrara H, Heckmann JM. Isoniazid exposure and pyridoxine levels in human immunodeficiency virus associated distal sensory neuropathy. *Int J Tuberc Lung Dis*. 2015;19(11):1312–9.
4. Porter K, Hoey L, Hughes CF, Ward M, McNulty H. Causes, consequences and public health implications of low B-vitamin status in ageing. *Nutrients*. 2016;8(11):725.
5. di Salvo ML, Safo MK, Contestabile R. Biomedical aspects of pyridoxal 5'-phosphate availability. *Front Biosci (Elite Ed)*. 2012;4:897–913.
6. Steen G, Vlasveld LTH, Poot CC, Slot-Verhousen A, Castel AJ. Onderzoek naar referentiewaarden van laboratoriumonderzoek in een algemeen ziekenhuis: resultaten en bevindingen. *Ned Tijdschr Klin Chem Labgeneesk*. 2009;34(1):35–43.
7. Health Council of the Netherlands. Dietary Reference Intakes: vitamin B₆, folic acid, and vitamin B₁₂. 2003/04. 2003. The Hague. Ref Type: Report.
8. Scientific Committee on Food, Scientific Panel on Dietetic Products NaA. Tolerable uptake levels for vitamins and minerals. http://www.efsa.europa.eu/sites/default/files/efsa_rep/blobserver_assets/ndatolerableuil.pdf. 2006 [cited 8 Sept 2017].
9. de Kruijk JR, Notermans NC. Sensory disturbances caused by multivitamin preparations. *Ned Tijdschr Geneesk*. 2005;149(46):2541–4.
10. Scott K, Zeris S, Kothari MJ. Elevated B₆ levels and peripheral neuropathies. *Electromyogr Clin Neurophysiol*. 2008;48(5):219–23.
11. Kulkantrakorn K. Pyridoxine-induced sensory ataxic neuropathy and neuropathy: revisited. *Neurol Sci*. 2014;35(11):1827–30.
12. Dalton K, Dalton MJ. Characteristics of pyridoxine overdose neuropathy syndrome. *Acta Neurol Scand*. 1987;76(1):8–11.
13. Ghavanini AA, Kimpinski K. Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess. *J Clin Neuromuscul Dis*. 2014;16(1):25–31.
14. van Hunsel F, Venhuis BJ, Keizers PH, Kant A. A 'natural' weight loss product containing sibutramine. *Drug Test Anal*. 2016;8(3–4):311–4.
15. Bijwerkingencentrum Lareb. Vitamine B₆ in (multi)vitamine preparaten en neuropathie. <https://www.lareb.nl/media/2991/pyridoxine-in-multivitaminpreparaten-en-neuropathie-overzicht.pdf> [cited 22 Feb 2018].
16. Bijwerkingencentrum Lareb. Vitamine B₆ in (multi)vitamine preparaten en neuropathie - update. https://www.lareb.nl/media/2927/signals_2016_pyridoxine_neuropathie_update.pdf. 2017. [cited 22 Feb 2018].
17. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). *Drug Saf*. 1999;20(2):109–17.
18. Bankowski Z, Bruppacher R, Crusius I. Reporting adverse drug reactions, definition of terms and criteria for their use. Council International Organizations of Medical Sciences (CIOMS). 32. 1999. Ref Type: Report.
19. CIOMS Working Group IV. Benefit-risk balance for marketed drugs: Evaluating safety signals. 1998. Geneva. Ref Type: Report.
20. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther*. 1981;30(2):239–45.
21. Hill AB. The environment and disease: association or causation? *Proc R Soc Med*. 1965;58:295–300.
22. Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. *Emerg Themes Epidemiol*. 2015;12:14.
23. Noren GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. *Stat Methods Med Res*. 2013;22(1):57–69.
24. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. *Eur J Clin Pharmacol*. 1998;54(4):315–21.
25. Mitwalli A, Blair G, Oreopoulos DG. Safety of intermediate doses of pyridoxine. *Can Med Assoc J*. 1984;131(1):14.
26. Brush MG, Bennett T, Hansen K. Pyridoxine in the treatment of premenstrual syndrome: a retrospective survey in 630 patients. *Br J Clin Pract*. 1988;42(11):448–52.
27. Williams MJ, Harris RI, Dean BC. Controlled trial of pyridoxine in the premenstrual syndrome. *J Int Med Res*. 1985;13(3):174–9.
28. European Commissionhealth & Consumer Protection Directorate-General. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Vitamin B. SCF/CS/NUT/UPPLEV/16 Final. 19-10-2000. 19-10-2000. Ref Type: Report.
29. Gdynia HJ, Muller T, Sperfeld AD, Kuhnlein P, Otto M, Kas-subek J, et al. Severe sensorimotor neuropathy after intake of highest dosages of vitamin B₆. *Neuromuscul Disord*. 2008;18(2):156–8.
30. Morra M, Philipszoon HD, D'Andrea G, Cananzi AR, L'Erario R, Milone FF. Sensory and motor neuropathy caused by excessive ingestion of vitamin B₆: a case report. *Funct Neurol*. 1993;8(6):429–32.
31. Foca FJ. Motor and sensory neuropathy secondary to excessive pyridoxine ingestion. *Arch Phys Med Rehabil*. 1985;66(9):634–6.

32. Peltier AC, Russell JW. Advances in understanding drug-induced neuropathies. *Drug Saf.* 2006;29(1):23–30.
33. Visser NA, Notermans NC, Degen LA, de Kruijk JR, van den Berg LH, Vrancken AF. Chronic idiopathic axonal polyneuropathy and vitamin B₆: a controlled population-based study. *J Peripher Nerv Syst.* 2014;19(2):136–44.
34. Edwards IR. Causality assessment in pharmacovigilance: still a challenge. *Drug Saf.* 2017;40(5):365–72.
35. Theophile H, Andre M, Miremont-Salame G, Arimone Y, Begaud B. Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference. *Drug Saf* 2013;36(10):1033–44.
36. Kane-Gill SL, Kirisci L, Pathak DS. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit? *Ann Pharmacother* 2005;39(11):1823–7.
37. Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality? *Pharmacoepidemiol Drug Saf* 2011;20(6):567–82.
38. Rolfes L, Kolfshoten J, van Hunsel F, van Puijenbroek E. The validity and reliability of a signal impact assessment tool. *Pharmacoepidemiol Drug Saf.* 2016;25(7):815–9.
39. Russom M, Tesfai D, Gebregiorgis S, Usman A, Mihreteab S, Bahta I, et al. Artesunate/amodiaquine-induced acute extrapyramidal reactions in children and younger adults: case series assessment. *Drug Saf.* 2016;39(8):763–8.
40. EFSA Panel on Dietetic Products NaAN. Dietary reference values for vitamin B₆. *EFSA J* 2016;14(6):4485.
41. Dodge T, Kaufman A. What makes consumers think dietary supplements are safe and effective? The role of disclaimers and FDA approval. *Health Psychol.* 2007;26(4):513–7.
42. Netherlands Food and Consumer Product Safety Authority (NVWA). Vitamine B₆ uit voedingssupplementen BuRO NVWA. <https://www.nvwa.nl/documenten/risicobeoordeling/voedselveiligheid/archief/2016m/risicobeoordeling-buro-nvwa-inzake-veilige-maximaleruimte-voor-inname-van-vitamine-b6-uit-supplementen-naast-voeding>. 2016 [cited 4 July 2017]; Available from <https://www.nvwa.nl/>.
43. Rijksoverheid. Schippers stelt maximum norm vitamine B₆. <https://www.rijksoverheid.nl/actueel/nieuws/2016/12/16/schippers-stelt-maximum-norm-vitamine-b6>. 2016 [cited 6 Oct 2017].
44. Bernstein AL. Vitamin B₆ in clinical neurology. *Ann N Y Acad Sci.* 1990;585:250–60.
45. van Hunsel F, Harmark L, Pal S, Olsson S, van Grootheest K. Experiences with adverse drug reaction reporting by patients: an 11-country survey. *Drug Saf.* 2012;35(1):45–60.
46. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. *N Engl J Med.* 1983;309(8):445–8.
47. Dalton K. Pyridoxine overdose in premenstrual syndrome. *Lancet.* 1985;1(8438):1168–9.
48. Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. *Neurology.* 1985;35(10):1466–8.
49. de Zegher F, Przyrembel H, Chalmers RA, Wolff ED, Huijman JG. Successful treatment of infantile type I primary hyperoxaluria complicated by pyridoxine toxicity. *Lancet.* 1985;2(8451):392–3.
50. Friedman MA, Resnick JS, Baer RL. Subepidermal vesicular dermatosis and sensory peripheral neuropathy caused by pyridoxine abuse. *J Am Acad Dermatol.* 1986;14(5 Pt 2):915–7.
51. Waterston JA, Gilligan BS. Pyridoxine neuropathy. *Med J Aust.* 1987;146(12):640–2.
52. Albin RL, Albers JW, Greenberg HS, Townsend JB, Lynn RB, Burke JM Jr, et al. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. *Neurology.* 1987;37(11):1729–32.
53. Santoro L, Ragno M, Nucciotti R, Barbieri F, Caruso G. Pyridoxine neuropathy. A four-year electrophysiological and clinical follow-up of a severe case. *Acta Neurol (Napoli).* 1991;13(1):13–8.
54. Berger AR, Schaumburg HH, Schroeder C, Apfel S, Reynolds R. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. *Neurology.* 1992;42(7):1367–70.
55. Wyatt KM, Dimmock PW, Jones PW, Shaughn O'Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. *BMJ.* 1999;318(7195):1375–81.
56. Bacharach R, Lowden M, Ahmed A. Pyridoxine toxicity small fiber neuropathy with dysautonomia: a case report. *J Clin Neuromuscul Dis.* 2017;19(1):43–6.